Makoto Suematsu, president of the Japan Agency for Medical Research and Development (AMED), discusses AMED’s successful unification of Japan’s previously disparate systems for medical research funding; the strategic significance of the country’s strong footprint in regenerative medicine and rare diseases; and the organization’s internationalization strategy, propelled by the push to publish its major projects in English.
We aim to stimulate the biomedical industry and our main mission is to fast-track medical R&D and improve three different types of lives: lifespan, daily life, and quality of life
